Brief: CytoDyn Anticipates Revenue Commencing In August 2019 from Use of PA-14 and/or PRO 140 In Diagnostic Test
01/07/2019 11:55
July 1 (Reuters) - Cytodyn Inc CYDY.PK :
* CYTODYN ANTICIPATES REVENUE COMMENCING IN AUGUST 2019 FROM
USE
OF PA-14 AND/OR PRO 140 IN DIAGNOSTIC TEST
* CYTODYN INC - SIGNS NON-BINDING AGREEMENT FOR DIAGNOSTIC
LICENSE
AND SUPPLY AGREEMENT WITH INCELLDX FOR PA-14 AND/OR PRO 140
* CYTODYN - DEAL REPRESENTS IMMEDIATE REVENUE OPPORTUNITY AS
DIAGNOSTIC TEST FOR RECEPTOR OCCUPANCY & EXISTENCE OF CCR5 ON
CANCER TISSUE & IN HIV
Source text for Eikon: ID:nGNX223Ctt
Further company coverage: CYDY.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cytodyn
See all newsBrief: Cytodyn Appoints Robert E. Hoffman As Chief Executive Officer
Brief: Cytodyn Closes $17.5 Million Financing To Fund Continued Development Of Leronlimab
Brief: CytoDyn Inc Files For Offering Of Up To 120 Million Shares Of Common Stock By Selling Stockholder - SEC Filing
Brief: Cytodyn Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer